Beovu Now Available in Canada, Receives Positive Reimbursement Recommendation
Novartis Pharmaceuticals Canada has announced that Beovu (brolucizumab injection) is now available in Canada for the treatment of wet age-related macular degeneration (AMD). The anti-VEGF therapy for wet AMD offers the option for eligible patients to start on 3-month dosing intervals after the loading phase.2,3 Beovu has been reviewed by the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) and has received a positive recommendation for reimbursement by participating public health plans.1
“Novartis has a deep history in ophthalmology and an ongoing commitment to eliminating preventable blindness by bringing innovative treatments to patients with serious eye diseases. We are dedicated to continuing to invest in research and as well as programs that improve the lives of people with wet AMD and are very proud to bring this latest advancement to Canadians,” Andrea Marazzi, General Manager, Novartis Pharmaceuticals Canada, said in a company news release. “We are pleased that the clinical value and benefit of Beovu have been recognized by CADTH and look forward to collaborating with decision makers to ensure access to Canadians in a timely manner.”
Anti-vascular endothelial growth factor (anti-VEGF) therapy is widely regarded as the standard of care for patients with wet AMD. Approved by Health Canada in March 2020, Beovu is the latest available anti-VEGF therapeutic advance, addressing the strong need for a treatment that reduces the need for frequent follow up.